Skip to content
The Policy VaultThe Policy Vault

Jakafi (ruxolitinib tablets) — Cigna

Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Neutrophilia

Initial criteria

  • Patient has a CSF3R mutation OR Patient has a Janus Associated Kinase 2 (JAK2) mutation

Approval duration

1 year